版本:
中国

BRIEF-Tenax hires Ladenburg Thalmann to review strategic options

April 5 Tenax Therapeutics Inc

* Tenax Therapeutics announces review of strategic alternatives and business update

* Tenax Therapeutics - Ladenburg Thalmann engaged to assist in process

* Tenax Therapeutics - John Kelley resigns as CEO; Michael Jebsen, president and CFO, appointed as interim CEO

* Tenax Therapeutics - company continues to evaluate results of LEVO-CTS clinical trial

* Tenax - strategic review process includes merger, business combination, strategic investment into co, purchase, license or other acquisition of assets Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐